key: cord-0897013-wkwrwh23
authors: Awada, Bassem; Alam, Walid; Chalfoun, Maria; Araj, George; Bizri, Abdul Rahman
title: COVID-19 and Candida Duobushaemulonii Superinfection: a case report
date: 2021-06-16
journal: J Mycol Med
DOI: 10.1016/j.mycmed.2021.101168
sha: dd321f1a13ef0fc560b192c76d9eb883bc51c3a3
doc_id: 897013
cord_uid: wkwrwh23

INTRODUCTION: Critically ill COVID-19 patients are at high risk for nosocomial bacterial and fungal infections due to several predisposing factors such as intensive care unit stay, mechanical ventilation, and broad-spectrum antibiotics. Data regarding multidrug resistant (MDR) Candida species in COVID-19 patients is scarce, and nonexistent regarding Candida duobushaemulonii superinfections. CASE DESCRIPTION: A 34-year-old male presented to our institution with acute respiratory distress syndrome (ARDS) due to COVID-19 infection and developed Candida duobushaemulonii fungemia after multiple courses of antibiotics and prolonged mechanical ventilation. He died after recurrent pneumothorax led to respiratory failure and cardiac arrest. DISCUSSION: Bacterial and fungal infections are common complications of viral pneumonia in critically ill patients. Data regarding these infections in COVID-19 patients has been poorly studied with only a few cases reporting secondary infection, mostly without identifying specific pathogens. Prolonged hospital stays, invasive interventions (central venous catheter, mechanical ventilation), and the use of broad-spectrum antibiotics in COVID-19 infections could carry a high risk of bacterial and/or fungal superinfections. CONCLUSION: Strategies to improve outcome in COVID-19 ICU patients should include early recognition of candidemia and appropriate antifungal therapy.

1 Introduction: Critically ill COVID-19 patients are at high risk for nosocomial bacterial and 2 fungal infections due to several predisposing factors such as intensive care unit stay, mechanical 3 ventilation, and broad-spectrum antibiotics. Data regarding multidrug resistant (MDR) Candida 4 species in COVID-19 patients is scarce, and nonexistent regarding Candida duobushaemulonii 5 superinfections. 6 Case description: A 34-year-old male presented to our institution with acute respiratory distress 7 syndrome (ARDS) due to COVID-19 infection and developed Candida duobushaemulonii 8 fungemia after multiple courses of antibiotics and prolonged mechanical ventilation. He died 9 after recurrent pneumothorax led to respiratory failure and cardiac arrest. [2, 3] . In India, candidemia affected 15 critically ill coronavirus disease patients admitted to an 8 intensive care unit (ICU), with two third of cases attributed to multidrug resistant Candida auris 9 [4] . Data regarding multidrug resistant (MDR) Candida species in COVID-19 patients is scarce, 10 and nonexistent regarding Candida duobushaemulonii superinfections. Candida 11 duobushaemulonii is a yeast that is closely related to Candida auris and is emerging as a rare 12 cause of invasive fungal infections with a multidrug resistant profile [5] . 13 We report a case of Candida duobushaemulonii candidemia in a patient with prolonged 14 Antibiotics were discontinued following completion of fourteen days of therapy and 15 clinical improvement. Antifungal therapy with fluconazole was kept. Patient initially improved 16 clinically but he developed hypotension a week later with elevation of his inflammatory markers 17 [ Table 1 ]. Blood cultures were taken from his central line and peripheral lines. He was started on 18 inhaled colistin and tigecycline. Central line blood cultures grew Candida non-albicans, and 19 caspofungin was started. Speciation and susceptibility testing revealed Candida 20 duobushaemulonii, susceptible to flucytosine [ Table 2 ]. Susceptibility data for other anti-fungals 21 is not available. His stay was again complicated by recurrent pneumothoraces leading to 22 respiratory failure followed by cardiac arrest and death. immunocompromised or have received prior antifungal therapy [9] . COVID-19 has been found 3 to cause immune dysregulation and hyperinflammation in severe cases potentially contributing to 4 the development of nosocomial infections in severely ill patients [10, 11, 12] . Nevertheless, 5 limited data regarding bacterial and fungal infections in COVID-19 patients has been published 6 [6] . Although the mechanism is still unclear, patients with severe COVID-19 are at similar risk 7 of invasive fungal infections as patients with severe influenza [13] . However, a review of the 8 literature showed that even when secondary infection data was available, the antibiotics use rate 9 (94%-100%) was much higher than the reported incidence of secondary infection (10%-15%), 10 potentially increasing the risk of fungal infections due to endogenous fungi such as Candida 11 species [6, 7] . A meta-analysis found three studies that reported four fungal pathogens in 16 Candida duobushaemulonii has been found to be invasive and resistant to drugs [15] . In 2018, a 17 genomic study found that Candida auris and Candida duobushaemulonii were closely related 18 phylogenetically [16] . Recently, a study found that six patients admitted to the ICU for severe 19 COVID-19 were colonized by Candida auris and four of them developed candidemia. Testing 20 showed resistance of all strains to amphotericin-B and azoles but susceptibility to echinocandins 21 [17] . The increased reports of Candida auris co-infection in severely ill COVID-19 patients and phenotypic testing [18] . The study found that the prevalence of C. duobushaemulonii was likely 27 underestimated and that the species was initially associated with superficial infections before 28 emerging as a cause of invasive candidiasis. The identified isolates also showed reduced 29 susceptibility to fluconazole, itraconazole, and amphotericin B [18] . In our case, the pathogen 30 was found to be susceptible to flucytosine with casponfungin already having been started empirically, but speciation and susceptibility results had come out after the patient had already 1 died and were only available for flucytosine, voriconazole, and amphotericin B. Risk factors for 2 invasive candidemia include prolonged hospital stay, invasive interventions (central venous 3 catheter, mechanical ventilation), and the use of broad-spectrum antibiotics [19, 20] . The wide 4 use of empirical antibiotics in COVID-19 ICU patients could be a major cause of both bacterial 5 and fungal superinfections and warrants additional evaluation. The reliance on clinical 6 presentation, inflammatory markers, and radiological findings is insufficient to confirm 7 secondary infections and may lead to overuse of antibiotics empirically, while current data on 8 co-infections is limited [21] . 9 Antimicrobial stewardship programs aim to optimize antimicrobial use, improve patient 10 outcomes, and reduce harms from excess use, such as antimicrobial resistance [22] . However, 11 due to the lack of stewardship programs targeted at pandemics such as COVID-19, inpatient 12 antibiotic use may have proceeded unchecked for several months, potentially contributing to 13 antimicrobial resistance and the development of secondary bacterial and/or fungal infections 14 from unnecessary empirical use of broad-spectrum antibiotics [20, 23, 24 ].

Conclusion: 16 Severely ill COVID-19 are at high risk of developing nosocomial infections associated 17 with mechanical ventilation and the use of broad-spectrum antibiotics. Medical and invasive 18 procedures are potential routes of bacterial and fungal infections, with the latter though rare, is 19 associated with considerable mortality in critically ill patients. Strategies to improve outcome in 20 COVID-19 ICU patients should, therefore, include early recognition of candidemia and 21 appropriate antifungal therapy. Authors' contributions: 8 Dr. Bassem Awada contributed to writing the manuscript and data collection. 9 Dr. Walid Alam contributed to writing the manuscript, literature review, data analysis, 10 and revision of the manuscript 11 Maria Chalfoun contributed to writing the manuscript 12 Dr. George Araj contributed to writing the manuscript and data analysis 13 Dr. Abdul Rahman Bizri contributed to writing the manuscript, data analysis, and 14 revision of the manuscript 15   Tables and Figures: 16 

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

COVID-19-Associated Candidiasis (CAC): An Underestimated Complication in the Absence of Immunological Predispositions

Multidrug-Resistant Candida auris Infections in Critically Ill Coronavirus Disease Patients

Emerging Multidrug-Resistant Candida duobushaemulonii Infections in Panama Hospitals: Importance of Laboratory Surveillance and Accurate Identification

Bacterial and fungal infections in COVID-19 patients: A matter of concern

Invasive fungal infections in transplant recipients

Nosocomial Fungal Infections: Epidemiology, Infection Control, and Prevention

Predisposing factors and outcome of uncommon yeast speciesrelated fungaemia based on an exhaustive surveillance programme (2002-14)

Nosocomial infections associated to COVID-19 in the intensive care unit: clinical characteristics and outcome

Hypercoagulability in COVID-19: A review of the potential mechanisms underlying clotting disorders

Neutrophils in COVID-19

Invasive fungal diseases during COVID-19: We should be prepared

Co-infections in people with COVID-19: a systematic review and metaanalysis

Identification and antifungal susceptibility profiles of Candida haemulonii species complex clinical isolates from a multicenter study in China

Genomic insights into multidrug-resistance, mating and virulence in Candida auris and related emerging species

Spread of Carbapenem-Resistant Gram-Negatives and Candida auris during the COVID-19 Pandemic in Critically Ill Patients: One Step Back in Antimicrobial Stewardship?

Candida duobushaemulonii: An Old But Unreported Pathogen

COVID-19 associated invasive candidiasis

Antibiotic exposure as a risk factor for fluconazole-resistant Candida bloodstream infection

Co-infections in COVID-19 critically ill and antibiotic management: a prospective cohort analysis

Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis